Ventyx Biosciences (NASDAQ:VTYX) Shares Gap Down to $36.43

Ventyx Biosciences, Inc. (NASDAQ:VTYXGet Rating) gapped down prior to trading on Wednesday . The stock had previously closed at $36.43, but opened at $35.45. Ventyx Biosciences shares last traded at $36.76, with a volume of 390 shares changing hands.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. HC Wainwright lifted their price objective on Ventyx Biosciences from $36.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, September 13th. Canaccord Genuity Group lifted their price objective on Ventyx Biosciences from $30.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, August 17th. Oppenheimer boosted their price target on Ventyx Biosciences from $40.00 to $65.00 and gave the stock an “outperform” rating in a report on Monday, September 12th. Canaccord Genuity Group boosted their price target on Ventyx Biosciences from $30.00 to $35.00 in a report on Wednesday, August 17th. Finally, Stifel Nicolaus boosted their price target on Ventyx Biosciences from $45.00 to $53.00 and gave the stock a “buy” rating in a report on Friday, September 16th. Ten equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $47.89.

Ventyx Biosciences Stock Performance

The business has a 50-day moving average of $21.97 and a two-hundred day moving average of $16.95.

Ventyx Biosciences (NASDAQ:VTYXGet Rating) last issued its quarterly earnings data on Monday, August 15th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.08. On average, analysts forecast that Ventyx Biosciences, Inc. will post -1.82 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ventyx Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of VTYX. venBio Partners LLC bought a new stake in shares of Ventyx Biosciences in the 4th quarter valued at about $99,529,000. Third Point LLC bought a new stake in shares of Ventyx Biosciences in the 4th quarter valued at about $83,083,000. Citadel Advisors LLC bought a new stake in shares of Ventyx Biosciences in the 4th quarter valued at about $74,736,000. FMR LLC grew its position in shares of Ventyx Biosciences by 92.9% in the 2nd quarter. FMR LLC now owns 1,575,942 shares of the company’s stock valued at $19,274,000 after buying an additional 758,903 shares during the last quarter. Finally, Great Point Partners LLC bought a new stake in shares of Ventyx Biosciences in the 1st quarter valued at about $4,564,000. Institutional investors own 68.03% of the company’s stock.

About Ventyx Biosciences

(Get Rating)

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus.

Further Reading

Receive News & Ratings for Ventyx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventyx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.